Mutant fragments of OspA and methods and uses relating thereto
The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
1. A polypeptide comprising a mutant fragment of a Borrelia outer surface protein A (OspA), wherein said mutant OspA fragment comprises SEQ ID NO: 217, or a variant thereof, wherein said variant has at least 95% sequence identity to a wild-type serotype 1 OspA fragment defined by amino acid residues 126-273 of SEQ ID NO: 20, and wherein said variant differs from said wild-type serotype 1 OspA fragment at least by the addition of at least one disulfide bond.
2. A pharmaceutical composition comprising the polypeptide according to claim 1 .
3. The pharmaceutical composition of claim 2 , further comprising a pharmaceutically acceptable carrier or excipient.
4. The pharmaceutical composition according to claim 3 , wherein said excipient is L-methionine and/or aluminium hydroxide.
5. A pharmaceutical composition comprising Lip-S1D1-S2D1 (SEQ ID NO: 186) and Lip-S5D1-S6D1 (SEQ ID NO: 190).
6. The pharmaceutical composition of claim 5 , further comprising a pharmaceutically acceptable carrier or excipient.
7. The pharmaceutical composition according to claim 6 , wherein said excipient is L-methionine and/or aluminium hydroxide.
8. A vaccine comprising Lip-S1D1-S2D1 (SEQ ID NO: 186) and Lip-S5D1-S6D1 (SEQ ID NO: 190).
9. The vaccine of claim 8 , further comprising a pharmaceutically acceptable carrier or excipient.
10. The vaccine according to claim 9 , wherein said excipient is L-methionine and/or aluminum hydroxide.